Asthma drug rejection rocks UK pharma

Asthma drug rejection rocks UK pharma

Hikma (HIK) and Vectura's (VEC) joint effort to launch the first unbranded version of GlaxoSmithKline's (GSK) top-selling asthma drug, Advair, has hit a roadblock. The two companies - which filed their drug with the US Food and Drug Administration (FDA) in 2016 - have had their initial application rejected, meaning they no longer expect to launch this year.

To continue reading, register today

to enjoy limited access to the following:

  • Daily trading news
  • Funds coverage
  • Features on big investment themes
  • Comprehensive companies coverage
  • Economic analysis
Subscribe to Investors Chronicle

Related topics

Subscribe today

Full access for just £3.37 a week:

• Tips and recommendations - to beat the market 
• Portfolio clinic & Mr Bearbull - build a well-planned portfolio 
• Expert tools - track and manage investments effortlessly
• Plus free delivery to your home or office

Subscribe Now